s8habio2

Property	Value
?:abstract	INTRODUCTION/OBJECTIVE: The general public may utilize online information through search engines for implications and risks of some anti-rheumatic drugs. These drugs have been used in the management of coronavirus disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of infection. Therefore, the objective of this study was to investigate the population-level interest in anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency data. METHOD: To obtain the relative search volume (RSV) of anti-rheumatic drugs, we queried Google Trends for 78 search terms representing non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, antigout agents, conventional disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, biologics, and Janus kinase (JAK) inhibitors within the USA. Three 8-week periods in 2020 (March 15–May 9), (May 10–July 4), and (July 5–August 29) representing the initial- and short-term periods were compared to overlapping periods of the preceding 3 years (2017–2019). RESULTS: We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years. CONCLUSION: There were significant increases in RSV of colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial- and short-term COVID-19 periods when compared to overlapping periods of the preceding 3 years reflecting a heightened level of information-seeking on these drugs during the pandemic. Rheumatologists should address this increase in informational demand. Further research assessing medium- and long-term interest in anti-rheumatic drugs is required to increase our knowledge on this new pandemic.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0003191> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0003211> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0005515> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0018100> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0242708> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C0543419> <https://research.tib.eu/covid-19/entity/s8habio2_hasAnnotation_C3854325>
?:creator	<https://research.tib.eu/covid-19/entity/Karde%C5%9F%2C_Sinan%3B_Kuzu%2C_Ali_Suat%3B_Pakhchanian%2C_Haig%3B_Raiker%2C_Rahul%3B_Karag%C3%BClle%2C_Mine>
?:doi	<https://research.tib.eu/covid-19/entity/10.1007/s10067-020-05490-w>
?:doi	10.1007/s10067-020-05490-w
?:journal	Clin_Rheumatol
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/b92ec1b20f79f64148c6bab9149c5db901c0efed.json
?:pmc_json_files	document_parses/pmc_json/PMC7603411.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7603411>
?:pmid	<https://research.tib.eu/covid-19/entity/33130946.0>
?:pmid	33130946.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/s8habio2_HAS_C0003191_COEXISTS_WITH_C1521863>
?:sha_id	<https://research.tib.eu/covid-19/entity/b92ec1b20f79f64148c6bab9149c5db901c0efed>
?:source	Medline; PMC
?:title	Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-31

Property

Value

?:abstract

INTRODUCTION/OBJECTIVE: The general public may utilize online information through search engines for implications and risks of some anti-rheumatic drugs. These drugs have been used in the management of coronavirus disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of infection. Therefore, the objective of this study was to investigate the population-level interest in anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency data. METHOD: To obtain the relative search volume (RSV) of anti-rheumatic drugs, we queried Google Trends for 78 search terms representing non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, antigout agents, conventional disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, biologics, and Janus kinase (JAK) inhibitors within the USA. Three 8-week periods in 2020 (March 15–May 9), (May 10–July 4), and (July 5–August 29) representing the initial- and short-term periods were compared to overlapping periods of the preceding 3 years (2017–2019). RESULTS: We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years. CONCLUSION: There were significant increases in RSV of colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial- and short-term COVID-19 periods when compared to overlapping periods of the preceding 3 years reflecting a heightened level of information-seeking on these drugs during the pandemic. Rheumatologists should address this increase in informational demand. Further research assessing medium- and long-term interest in anti-rheumatic drugs is required to increase our knowledge on this new pandemic.

is ?:annotates of